Rigel Pharmaceuticals (RIGL) EBITDA Margin (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly EBITDA Margin of 20.21% for Q1 2026, down 374.0% year-over-year from 7.37% in Q1 2025, and down 39.13% quarter-over-quarter from 33.19% in Q4 2025.
Rigel Pharmaceuticals (RIGL) EBITDA Margin (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' EBITDA Margin history runs 16 years deep, the most recent figure standing at 20.21% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 374.0% year-over-year to 20.21%; the TTM figure through Mar 2026 stood at 41.56% (up 1993.0% YoY), while the FY2025 annual figure was 42.63%, up 2914.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 20.21%, down from 33.19% in the prior quarter.
- The five-year high for EBITDA Margin was 60.09% in Q2 2025, with the low at 156.92% in Q1 2022.
- The 5-year median for EBITDA Margin is 4.05% (2022), against an average of 8.64%.
- Peak annual rise in EBITDA Margin reached 10900 bps in 2022, while the deepest fall reached 20846 bps in 2022.
- Rigel Pharmaceuticals' EBITDA Margin stood at 4.05% in 2022, then jumped by 35 bps to 5.49% in 2023, then jumped by 426 bps to 28.92% in 2024, then gained by 15 bps to 33.19% in 2025, then slumped by 39 bps to 20.21% in 2026.
- Business Quant data shows RIGL's EBITDA Margin at 20.21% in Q1 2026, 33.19% in Q4 2025, and 40.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 29.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.95% |
| Mar 31, 2026 | 20.21% |
| Dec 31, 2025 | 33.19% |
| Sep 30, 2025 | 40.91% |
| Jun 30, 2025 | 60.09% |
| Mar 31, 2025 | 23.95% |
| Dec 31, 2024 | 28.92% |
| Sep 30, 2024 | 25.41% |
| Jun 30, 2024 | 1.21% |
| Mar 31, 2024 | -23.59% |
| Dec 31, 2023 | 5.49% |
| Sep 30, 2023 | -15.87% |
| Jun 30, 2023 | -19.59% |
| Mar 31, 2023 | -48.81% |
| Dec 31, 2022 | 4.05% |
| Sep 30, 2022 | -82.12% |
| Jun 30, 2022 | -43.48% |
| Mar 31, 2022 | -156.92% |
| Dec 31, 2021 | -104.94% |
| Sep 30, 2021 | -91.84% |